Last 8 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q4 '23 | Q3 '23 |
|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -0.01 | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | |
| P/S Ratio | — | 190.73 | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | |
| P/B Ratio | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | |
| P/FCF | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Aspire Biopharma Holdings, Inc.'s operating margin was -59015.8% in Q3 2025.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q4 '23 | Q3 '23 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | 45.5% | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | |
| Operating Margin | — | -59015.8% | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | |
| Net Margin | — | -95337.1% | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q4 '23 | Q3 '23 |
|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | — | — | — | — | -21.9% | -0.8% | -0.3% |
| — | — | — | — | — | — | — | — | — | |
| ROA | -12913.9% | -109.1% | -134.1% | -1508.5% | -7207.8% | -9.3% | -3.8% | -0.8% | -0.3% |
| — | -1072.0% | -3431.7% | -195757.0% | -2188054.9% | — | — | — | — | |
| ROIC | — | — | — | — | — | -104.8% | -19.9% | -0.6% | — |
| — | — | — | — | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
The current ratio has weakened 7.1% YoY to 0.17x, tightening the short-term liquidity position.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q4 '23 | Q3 '23 |
|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — | 1.01 | — | — |
| — | — | — | — | — | — | — | — | — | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | |
| Current Ratio | 0.09 | 0.17 | 0.09 | 0.22 | 0.09 | 0.19 | 0.06 | 0.09 | 0.80 |
| — | -7.1% | +44.4% | +156.3% | -89.1% | — | — | — | — | |
| Quick Ratio | 0.09 | 0.17 | 0.09 | 0.22 | 0.09 | 0.19 | 0.06 | 0.09 | 0.80 |
| — | -8.5% | +44.4% | +156.3% | -89.1% | — | — | — | — | |
| Interest Coverage | -3.46 | -0.77 | -1.52 | -53.65 | -5.12 | -74.24 | -0.47 | -8.51 | — |
| — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 8 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare performance and metrics against top competitors.
Start ComparisonAspire Biopharma Holdings, Inc.'s current P/E is -0.0x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Aspire Biopharma Holdings, Inc.'s business trajectory between earnings reports.